Advanced Development of the rF1V and rBV AB Vaccines : Progress and Challenges
Joint Authors
Hart, Mary Kate
Saviolakis, George A.
House, Robert V.
Welkos, Susan L.
Source
Advances in Preventive Medicine
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-14, 14 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-10-17
Country of Publication
Egypt
No. of Pages
14
Main Subjects
Abstract EN
The development of vaccines for microorganisms and bacterial toxins with the potential to be used as biowarfare and bioterrorism agents is an important component of the US biodefense program.
DVC is developing two vaccines, one against inhalational exposure to botulinum neurotoxins A1 and B1 and a second for Yersinia pestis, with the ultimate goal of licensure by the FDA under the Animal Rule.
Progress has been made in all technical areas, including manufacturing, nonclinical, and clinical development and testing of the vaccines, and in assay development.
The current status of development of these vaccines, and remaining challenges are described in this chapter.
American Psychological Association (APA)
Hart, Mary Kate& Saviolakis, George A.& Welkos, Susan L.& House, Robert V.. 2011. Advanced Development of the rF1V and rBV AB Vaccines : Progress and Challenges. Advances in Preventive Medicine،Vol. 2012, no. 2012, pp.1-14.
https://search.emarefa.net/detail/BIM-494235
Modern Language Association (MLA)
Hart, Mary Kate…[et al.]. Advanced Development of the rF1V and rBV AB Vaccines : Progress and Challenges. Advances in Preventive Medicine No. 2012 (2012), pp.1-14.
https://search.emarefa.net/detail/BIM-494235
American Medical Association (AMA)
Hart, Mary Kate& Saviolakis, George A.& Welkos, Susan L.& House, Robert V.. Advanced Development of the rF1V and rBV AB Vaccines : Progress and Challenges. Advances in Preventive Medicine. 2011. Vol. 2012, no. 2012, pp.1-14.
https://search.emarefa.net/detail/BIM-494235
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-494235